Summary
The psoralen derivative methoxsalen and to a lesser extent some other furocoumarin congeners, including bergapten and trioxsalen, have acquired a place in the treatment of psoriasis and other dermatoses. They are inactive after oral or topical administration unless combined with irradiation with long-wave ultraviolet light (UVA). This combination is referred to as photochemotherapy or PUVA (psoralen plus UVA). Usually a standard dose of methoxsalen (0.5 to 0.7 mg/kg) is given 2 hours prior to irradiation, and the light dose is assessed individually. Differences in response are often due to the unpredictable pharmacokinetic behaviour of the drug.
Reversed-phase high-performance liquid chromatography is the method of choice for determining methoxsalen concentrations in body fluids, but gas chromatography with electron capture detection and thin-layer chromatography with fluorescence densitometry also give favourable results.
The absorption of methoxsalen, and hence clinical response, is affected by concomitant food ingestion and by differences in drug formulation. A liquid preparation in soft gelatin capsules or a microenema give higher and more rapidly appearing maximum serum concentrations (Cmax) than crystalline methoxsalen in tablets or capsules.
With a standard dose of tablets, Cmax is in the range of 50 to 250 µg/L and appears between 1 and 2 hours after ingestion. The drug has a high, but variable, intrinsic metabolic clearance and is almost completely metabolised. Serum elimination half-life is in the order of 0.5 to 2 hours. There is a large interpatient variability in the clearance of methoxsalen (40 to 650 L/h); the relative distribution volume ranges between I and 9 L/kg. Concentrations in suction blister fluid (sbf) are approximately one-third of Cmax in serum and remain relatively constant as long as the plasma concentration exceeds the suction blister fluid level.
Individuals with a high methoxsalen clearance and low Cmax usually show less biological sensitivity to PUVA (in terms of minimal phototoxic dose of UVA) than low-clearance patients and frequently a less favourable clinical response. Hence Cmax can be used for the purpose of therapeutic drug monitoring and, in practice, this may be determined by measuring serum concentrations at least at 1, 2, and 3 hours after ingestion.
Bergapten is somewhat less active than methoxsalen but has similar pharmacokinetic characteristics. The bioavailability of trioxsalen is poor after oral intake and this drug is mainly administered topically.
Similar content being viewed by others
References
Andersen KE, Menne T, Gammeltoft M, Hjorth N, Larsen E, et al. Pharmacokinetic and clinical comparison of two 8-methoxypsoralen brands. Archives of Dermatological Research 268: 23–29, 1980
Artuc M, Stuettgen G, Schalla W, Schaefer H, Gazith J. Reversible binding of 5- and 8-methoxypsoralen to human serum proteins (albumin) and to epidermis in vitro. British Journal of Dermatology 101: 669–677, 1979
Beani JC, Sarrazin C, Amblard P, Reymond JL, Beriel H, et al. Comparison between plasma levels of 8-methoxypsoralen and skin photosensitivity: the interest of pharmacokinetic studies during photochemotherapy of psoriasis. Dermatology 166: 169–174, 1983
Bevilacqua R, Benassi CA, Schiavon O, Veronese FM. Drug protein interaction: displacement of albumin bound 8-methoxypsoralen by drugs. Farmaco-Edizione Scientifica 36: 598–605, 1981
Biais J, Dubertret L, Gaboriau F, Vigny P. Fluorescence detection of an 8-methoxypsoralen metabolite in human interstitial fluid. Photochemistry and Photobiology 35: 423–426, 1982
Boven M van, Daenens P. Determination of 8-methoxypsoralen in human plasma by electron capture gas-liquid chromatography. Journal de Pharmacie de Belgique 35: 103–106, 1980
Busch U, Schmid J, Koss FW, Zipp H, Zimmer A. Pharmacokinetics and metabolite-pattern of 8-methoxypsoralen in man following oral administration as compared to the pharmacokinetics in rat and dog. Archives of Dermatological Research 262: 255–265, 1978
Chakrabarti SG, Gooray DA, Kenney JA. Determination of 8-methoxypsoralen in plasma by scanning fluorometry after thin-layer chromatography. Clinical Chemistry 24: 1155–1157, 1978
Chakrabarti SG, Grimes PE, Minus HR, Kenney JA, Pradhan TK. Determination of trimethylpsoralen in blood, ophthalmic fluids, and skin. Journal of Investigative Dermatology 79: 374–377, 1982
Chakrabarti SG, Grimes PE, Minus HR, Kenney JA, Pradhan TK. Serum concentrations of trimethylpsoralen after oral administration. Journal of Investigative Dermatology 81: 289–290, 1983
Chrétien P, Galmiche JP, Payenneville JM, Fouin-Fortunet H, Lauret P, et al. Effects of oral methoxy-psoralen photochemotherapy (PUVA) on liver function and antipyrin kinetics. International Journal of Clinical Pharmacology Research 3: 343–347, 1983
Confalone PN, Confalone DL. Total synthesis of the major metabolite of methoxsalen. Journal of Organic Chemistry 45: 1470–1473, 1980
Coupez L, Agache PG, Petigny M. Effect of UV-B erythema of psoralen, trimethylpsoralen, and 8-methoxypsoralen. Acta Dermato-Venereologica (Stockholm) 60: 456–459, 1980
Danno K, Horio T, Ozaki M, Imamura S. Topical 8-methoxypsoralen photochemotherapy of psoriasis: a clinical study. British Journal of Dermatology 108: 519–524, 1983
De Bersaques J, Monbaliu JG, Hindryckx Ph. Relationship between 8-methoxypsoralen plasma levels and phototoxic effect. Dermatology 167: 135–137, 1983
De Bersaques J, Monbaliu J, Belpaire F, Bogaert M. 8-Methoxy-psoralen plasma levels and phototoxic effect. Acta Dermatolgica Venereologica (Stockholm) 113: (Suppl.) 166–167, 1984
Drake LA, Megaw J, Lerman S. Determination of serum and skin levels of 8-methoxypsoralen by phosphorescence spectroscopy. Clinical Research 31: 563A, 1983
Ehrsson H, Eksborg S, Wallin I, Kallberg N, Swanbeck J. Determination of 8-methoxypsoralen in plasma by electron capture gas chromatography. Journal of Chromatography 140: 157–164, 1977
Ehrsson H, Nilsson S-O, Ehrnebo M, Wallin I, Wennersten G. Effect of food on kinetics of 8-methoxypsoralen. Clinical Pharmacology and Therapeutics 25: 167–171, 1979
Fincham N, Greaves MW, Hensby CN, Vella Briffa D. The quantitative analysis of 8-MOP in human plasma by HPLC-UV. British Journal of Pharmacology 63: 373P, 1978
Fischer T, Alsins J. Treatment of psoriasis with trioxsalen baths and dysprosium lamps. Acta Dermato-Venereologica (Stockholm) 56: 383–390, 1976
Fitzpatrick TB, Arndt KA, Clark WH, Eisen AZ, van Scott EJ, et al. Dermatology in general medicine, 1st ed., p. 220, McGraw-Hill, Blakiston Publication, New York, 1971
Gazith J, Schaefer H. 8-Methoxypsoralen: its isolation and gas chromatographic determination from aqueous solutions and serum. Biochemical Medicine 18: 102–109, 1977
Gazith J, Schalla W, Schaefer H. 8-Methoxypsoralen-gas chromatographic determination and serum kinetics. Archives of Dermatological Research 263: 215–222, 1978
Gilchrest BA. Methoxsalen photochemotherapy for mycosis fungoides. Cancer Treatment Reports 63: 663–667, 1979
Glew WB, Roberts WP, Malinin GI, Nigra TP. Quantitative determination by bioassay of photoactive 8-methoxypsoralen in serum. Journal of Investigative Dermatology 75: 230–234, 1980
Goldstein DP, Carter DM, Ljunggren B, Burkholder, J. Minimal phototoxic doses and 8-MOP plasma levels in PUVA patients. Journal of Investigative Dermatology 78: 429–433, 1982
Hannuksela M, Karvonen, J. Topical trioxsalen PUVA therapy. ActaDermato-Venereologica (Stockholm) 113 (Suppl.): 135–138, 1984
Hensby CN. The qualitative and quantitative analysis of 8-methoxypsoralen by HPLC-UV and GLC-MS. Clinical Experimental Dermatology 3: 355–366, 1978
Henseler T, Wolff K, Hönigsmann H, Christophers E. Oral 8-methoxypsoralen photochemotherapy of psoriasis. Lancet 1: 853–857, 1981
Herfst MJ, Koot-Gronsveld EAM, De Wolff FA. Serum levels of 8-methoxypsoralen in psoriasis patients using a new fluoro-densitometric method. Archives of Dermatological Research 262: 1–6, 1978
Herfst MJ, Van Rees H. Suction blister fluid as a model for interstitial fluid in rats. Archives of Dermatological Research 263: 325–334, 1978
Herfst MJ, Edelbroek PM, de Wolff FA. Determination of 8-methoxypsoralen in suction blister fluid and serum by liquid chromatography. Clinical Chemistry 26: 1825–1828, 1980
Herfst MJ, de Wolff FA. Difference in bioavailability between two brands of 8-methoxypsoralen and its impact on the clinical response in psoriatic patients. British Journal of Clinical Pharmacology 13: 519–522, 1982a
Herfst MJ, de Wolff FA. Influence of food on the kinetics of 8-methoxypsoralen in serum and suction blister fluid in psoriatic patients. European Journal of Clinical Pharmacology 23: 75–80, 1982b
Herfst MJ. Pharmacological aspects of PUVA therapy. Thesis, Leiden, 1982
Herfst MJ, de Wolff FA. Intraindividual and interindividual variability in 8-methoxypsoralen kinetics and effect in psoriatic patients. Clinical Pharmacology and Therapeutics 34: 117–124, 1983
Hofwegen PM van, Winkelman, A. About 8-methoxypsoralen: difference in the efficiency of two delivery forms. Dermatologica 158: 307, 1979
Hönigsmann H, Jaschke E, Gschnait F, Brenner W, Fritsch P, et al. 5-Methoxypsoralen (Bergapten) in photochemotherapy of psoriasis. British Journal of Dermatology 101: 369–378, 1979
Hönigsmann H, Jaschke E, Nitsche V, Brenner W, Rauschmeier W, et al. Serum levels of 8-methoxypsoralen in two different drug preparations — correlation with photosensitivity and UV-A dose requirements for photochemotherapy. Journal of Investigative Dermatology 79: 233–236, 1982
Jansén CT, Karvonen J, Malmiharju T. PUVA therapy for polymorphous light eruptions: comparison of systemic methoxsalen and topical trioxsalen regimens and evaluation of local protective mechanisms. Acta Dermato-Venereologica (Stockholm) 62: 317–320, 1982
Jansén CT, Tuomi A. Improved methoxypsoralen skin absorption from a novel basal formulation. Acta Pharmaceutica Suecica 20: 40–41, 1983
Jansén CT, Wilén G, Ylitalo P, Malmiharju T. Inter- and intraindividual variations in serum methoxsalen levels during repeated oral exposure. Current Therapeutic Research 33: 258–264, 1983a
Jansén CT, Wilén G, Paul R. Variations in skin photosensitization during repeated oral 8-methoxypsoralen medication. Archives of Dermatological Research 275: 315–317, 1983b
Kammerau B, Klebe U, Zesch A, Schaefer H. Penetration, permeation, and resorption of 8-methoxypsoralen. Archives of Dermatological Research 255: 31–42, 1976
Kolis SJ, Williams TH, Postma EJ, Sasso GJ, Confalone PN, et al. The metabolism of l4C-methoxsalen by the dog. Drug Metabolism and Disposition 7: 220–225, 1979
Korting HCh, Schäfer-Korting M, Roser-Maass E, Mutschier E. Determination of 8-methoxypsoralen levels in plasma and skin suction blister fluid by a new sensitive fluorodensitometric method. Archives of Dermatological Research 272: 9–20, 1982
Langner A, Wolska H. New galenical form of 8-methoxypsoralen in photochemotherapy of psoriasis. Archives of Dermatological Research 271: 461–462, 1981
Lauharanta J, Juvakoski T, Kanerva L, Lassus A. Pharmacokinetics of 8-methoxypsoralen in serum and suction blister fluid. Archives of Dermatological Research 273: 111–114, 1982
Levins PC, Gange RW, Momtaz- TK, Parrish JA, Fitzpatrick TB. A new liquid formulation of 8-MOP: bioactivity and effect of diet. Journal of Investigative Dermatology 82: 185–187, 1984
Ljunggren B, Carter M, Albert J, Reid T. Plasma levels of 8-MOP determined by high-pressure liquid chromatography in psoriatic patients ingesting drug from 2 manufacturers. Journal of Investigative Dermatology 74: 59–62, 1980
Ljunggren B, Bjellerup M, Carter DM. Dose-r-sponse relations in phototoxicity due to 8-methoxypsoralen and UV-A in man. Journal of Investigative Dermatology 76: 73–75, 1981
Mandula BB, Pathak MA. Metabolic reactions in vitro of psoralens with liver and epidermis. Biochemical Pharmacology 28: 127–132, 1979
Marciani S, Guiotto A, Rodighiero P, Gia O, Rodighiero G, et al. Synthesis and photobiological properties of 4,8-dimethyl-5’-carboxypsoralen: a major metabolite of 4,5’,8-trimethyl-psoralen. Farmaco-Edizione Scientifica 34: 234–247, 1979
Melski JW, Tanenbaum L, Parrish JA, Fitzpatrick TB, Bleich HL, et al. Oral methoxsalen photochemotherapy for the treatment of psoriasis: a cooperative clinical trial. Journal of Investigative Dermatology 68: 328–335, 1977
Menne T, Andersen KE, Larsen E, Solgaard P. Pharmacokinetic comparison of seven 8-methoxypsoralen brands. Acta Dermato-Venereologica (Stockholm) 61: 137–140, 1981
Monbaliu JG, Bogaert MG, De Bersaques J, Hindryckx Ph. Problems with commercial formulations of 8-methoxypsoralen. Dermatologica 163: 468–473, 1981
Morison WL, White HAD, Gonzalez E, Parrish JA, Fitzpatrick TB. Oral methoxsalen photochemotherapy of uncommon photodermatoses. Acta Dermato-Venereologica (Stockholm) 59: 366–368, 1979
Mosher D, Momtaz K, Borowska Z, Caldwell D, Carter DM. Bioavailability of 8-methoxypsoralen: another determinant. Clinical Research 31: 590A, 1983
Neild VS, Scott LV. Plasma levels of 8-methoxypsoralen in psoriatic patients receiving topical 8-methoxypsoralen. British Journal of Dermatology 106: 199–203, 1982
Nitsche V, Raff M, Bardach H. 8-Methoxypsoralen (8-MOP) — a new galenic form and its relation to 8-MOP serum levels. Archives of Dermatological Research 271: 11–17, 1981
Parrish JA, Fitzpatrick TB, Tanenbaum L, Pathak MA. Photo-chemotherapy of psoriasis with oral methoxypsoralen and longwave ultraviolet light. New England Journal of Medicine 291: 1207, 1974
Polano MK, Schothorst AA. Difference in the efficiency of two delivery forms of 8-methoxypsoralen. Dermatologica 154: 216–218, 1977
Prognon P, Biais J, Vigny P, Averbeck D, Averbeck S, et al. The metabolism of 8-methoxypsoralen by saccharomyces cerevisiae. Evidence for an inducing effect of ethanol. Farmaco-Edizione Scientifica 39: 739–751, 1984
Roelandts R, Van Boven M, Deheyn T, Vander Stichele G, Degreef H, et al. Dietary influences on 8-MOP plasma levels in PUVA patients with psoriasis. British Journal of Dermatology 105: 569–572, 1981a
Roelandts R, Van Boven M, Adriaens P. Methoxsalen serum level variations in psoralen and ultraviolet-A (PUVA) therapy. Archives of Dermatology 117: 758, 1981b
Rogers SL, Staubus AE, Bianchine JR, Gerber N. Michaelis-Men-ten pharmacokinetics of 8-methoxypsoralen. Federation Proceedings 42: 1139, 1983
Schäfer-Korting M, Korting HCh. Intraindividual variations of 8-methoxypsoralen plasma levels. Archives of Dermatological Research 272: 1–7, 1982
Schimmer O, Fischer K. Metabolic inactivation of 8-methoxypsoralen (8-MOP) by rat-liver microsomal preparations. Mutation Research 79: 327–330, 1980
Schmid J, Koss FW. Rapid, sensitive gas chromatographic analysis of 8-methoxypsoralen in human plasma. Journal of Chromatography, Biomedical Application 146: 498–502, 1978
Schmid J, Prox A, Reuter A, Zipp H, Koss FW. The metabolism of 8-methoxypsoralen in man. European Journal of Drug Metabolism and Pharmacokinetics 5: 81–92, 1980a
Schmid J, Prox A, Zipp H, Koss FW. The use of stable isotopes to prove the saturable first-pass effect of methoxsalen. Biomedical Mass Spectrometry 7: 560–564, 1980b
Scott BR, Pathak MA, Mohn GR. Molecular and genetic basis of furocoumarin reactions. Mutation Research 39: 29–74, 1976
Sharp DE, Mays DC, Rogers SL, Guiler RC, Hecht S, et al. In vitro metabolism of 8-methoxypsoralen. Proceedings of the Western Pharmacology Society 27: 255–258, 1984
Siddiqui AH, Stolk L, Korthals Altes-Levij van Vinninghe HF, Kammeijer A, Cormane RH. Microenema of 8-methoxypso alen in photochemotherapy of psoriasis. Archives of Derma tological Research 273: 219–223, 1982
Siddiqui AH, Stolk LML, Cormane RH. Comparison of serum levels and clinical results of PUVA therapy with three different dosage forms of 8-methoxypsoralen. Archives of Dermatological Research 276: 343–345, 1984
Steiner I, Prey T, Gschnait F, Washüttl J, Greiter F. Serum level profiles of 8-methoxypsoralen after oral administration. Archives of Dermatological Research 259: 299–301, 1977
Steiner I, Prey T, Gschnait F, Washüttl J, Greiter F. Serum levels of 8-methoxypsoralen 2 hours after oral administration. Acta Dermato-Venereologica (Stockholm) 58: 185–188, 1978
Stern RS, Momtaz K. Skin typing for assessment of skin cancer risk and acute response to UV-B and oral methoxsalen photochemotherapy. Archives of Dermatology 120: 869–873, 1984
Stevenson IH, Kenicer KJA, Johnson BE, Frain-Bell W. Plasma 8-methoxypsoralen concentrations in photochemotherapy of psoriasis. British Journal of Dermatology 104: 47–51, 1981
Stolk LML. Determination of 8-methoxypsoralen in biological fluids by reverse phase HPLC. Pharmaceutisch Weekblad-Scientific Edition 2: 29–32, 1980
Stolk L, Kammeyer A, Cormane RH, Van Zwieten PA. Serum levels of 8-methoxypsoralen: difference between two oral methods of administration. British Journal of Dermatology 103: 417–420, 1980
Stolk L, Siddiqui AH, Kammeyer A, Cormane RH, Van Zwieten PA. Serum and saliva levels of 8-methoxypsoralen after rectal administration as a micro-enema. British Journal of Dermatology 104: 447–451, 1981a
Stolk LML, Westerhof W, Cormane RH, Van Zwieten PA. Serum and urine concentrations of 5-methoxypsoralen after oral administration. British Journal of Dermatology 105: 415–420, 1981b
Stolk L, Siddiqui AH, Cormane RH. Serum levels of trimethylpsoralen after oral administration. British Journal of Dermatology 104: 443–445, 1981c
Stolk LML, Siddiqui AH, Cormane RH. Serum concentrations of trimethylpsoralen after oral-administration. Journal of Investigative Dermatology 81: 289, 1983
Stolk LML, Siddiqui AH, Westerhof W, Cormane RH. Comparison of bioavailability and phototoxicity of two oral preparations of 5-methoxypsoralen. British Journal of Dermatology 112: 469–473, 1985
Swanbeck G, Ehrsson H, Ehrnebo M, Wallin I, Jonsson L. Serum concentration and phototoxic effect of methoxsalen in patients with psoriasis. Clinical Pharmacology and Therapeutics 25: 478–480, 1979
Thune P. Plasma levels of 8-methoxypsoralen and phototoxicity studies during PUVA treatment of psoriasis with Meladinin tablets. Acta Dermato-Venereologica (Stockholm) 58: 149–151, 1978
Thune P, Volden G. Photochemotherapy of psoriasis with relevance to 8-methoxypsoralen plasma level and low intensity irradiation. Acta Dermato-Venereologica (Stockholm) 57: 351–355, 1977
Tsamboas D, Vizethum W, Goerz G. Effect of oral 8-methoxypsoralen on rat liver microsomal cytochrome P-450. Archives of Dermatological Research 263: 339–342, 1978
Veronese FM, Bevilacqua R, Schiavon O, Rodighiero G. The binding of 8-methoxypsoralen by human serum albumin. Farmaco-Edizione Scientifica 33: 667–675, 1978
Veronese FM, Bevilacqua R, Schiavon O, Rodighiero G. Drug-protein interaction: plasma protein binding of furocoumarins. Farmaco-Edizione Scientifica 34: 716–725, 1979
Wagner G. Hofmann C, Busch U, Schmid J, Plewig C, 8-MOP plasma levels in PUVA problem cases with psoriasis. British Journal of Dermatology 101: 285–292, 1979
Wolff K, Gschnait F, Hönigsmann H, Konrad K, Parrish JA, et al. Phototesting and dosimetry for photochemotherapy. British Journal of Dermatology 96: 1–10, 1977
Wolff FA de, Herfst MJ, Edelbroek PM. Determination of 8-methoxypsoralen in human serum and suction blister fluid. In Oliver JS (Ed.) Forensic toxicology, pp. 67–70, Croom Helm, London, 1980
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
de Wolff, F.A., Thomas, T.V. Clinical Pharmacokinetics of Methoxsalen and Other Psoralens. Clin-Pharmacokinet 11, 62–75 (1986). https://doi.org/10.2165/00003088-198611010-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003088-198611010-00004